- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01739777
Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy (RIMECARD)
Phase 1 Randomized-Double Blind Clinical Trial of Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells Transplantation in Heart Failure on Patients With Cardiopathy in Dilated Stage, of Different Etiology
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Phase I-II Clinical Trial - Safety and efficacy of umbilical cord derived mesenchymal stem cells (ucMSC) in patients with heart failure Randomized, double blind, controlled prospective study in patients with compensated heart failure in dilated phase.
Thirty patients will be selected, who will undergo a strict 3-month followup of ventricular function before being sequentially randomized into two groups: the first group of 15 patients will receive a sole injection of ucMSC and the remaining 15 patients will comprise the control group.
Every patient will maintain their standard treatment of heart failure, with maximum tolerated dosage without side effects.
The day of infusion will be considered day zero. From that moment, followup will be divided into 0-3, 3-6, and 6-12 months.
Clinical results will be analyzed after completion of 12 months of followup.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Santiago de Chile, Chile
- Universidad de Los Andes
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Symptomatic heart failure patients in dilated stages
- Etiologies: dilated cardiomyopathy, chronic hypertensive cardiopathy in dilated stage, chronic coronary cardiopathy in dilated stage
- Ejection fraction ≤ 40%.
- Patients who are stable under optimal medical treatment for a period of at least 3 months prior to randomization
Exclusion Criteria:
- Severe or persistent heart failure
- Recurrent myocardial ischemia
- Uncontrolled ventricular tachycardia
- Malignant disease (life expectancy of less than one year)
- Manifest ventricular asynchrony
- Hematologic disease
- Recent cerebrovascular disease
- Recent acute coronary syndrome
- Serum creatinine >2.26 mg/dL (200 umol/L)
- Atrial fibrillation without heart rate control in the last 3 months
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: ucMSC
Umbilical cord derived mesenchymal are injected intravenously to Patients.
|
1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma
Andre navne:
|
Placebo komparator: Controls
Intravenous placebo solution are administrated to Patients.
|
Autologous Serum will administrated as placebo
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
• Change in global left ventricular ejection fraction
Tidsramme: 3, 6, 12 months
|
3, 6, 12 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
• Change in functional capacity measured in O2 consumption
Tidsramme: 0, 3, 6, 12 months
|
0, 3, 6, 12 months
|
• Occurrence of major adverse cardiac event
Tidsramme: 12 months
|
12 months
|
• Change in high sensitivity C-reactive protein (hs CRP)
Tidsramme: 0, 3, 6, 12 months
|
0, 3, 6, 12 months
|
• Reduction in level of B-type natriuretic peptide (BNP)
Tidsramme: 0, 3, 6, 12 months
|
0, 3, 6, 12 months
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Measures of anti & pro inflammatory cytokines profile
Tidsramme: 0-15-90 days
|
The cytokine profile we can determinate is Interleukin 1 Beta(IL-1b),Interleukin 6 (IL-6), soluble receptor TNF (TNFRs), tumor necrosis factor(TNF), Interleukin 10 (IL-10), Transforming Growth Factor beta (TGFb), Interferon-gamma (IFNg),Interleukin 17A (IL-17A),Interleukin-4(IL-4) by multiflex flow cytometer.
|
0-15-90 days
|
Change in quality of life
Tidsramme: 0-6-12 months
|
Measures by specific questionnaire of quality of life: Minnesota Living with Heart Failure Questionnaire (MLHFQ). Kansas, City Cardiomyopathy Questionnaire (KCCQ) |
0-6-12 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Jorge Bartolucci, Dr., Universidad de Los Andes
Publikationer og nyttige links
Generelle publikationer
- Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009 Dec 8;54(24):2277-86. doi: 10.1016/j.jacc.2009.06.055.
- Bartolucci J, Verdugo FJ, Gonzalez PL, Larrea RE, Abarzua E, Goset C, Rojo P, Palma I, Lamich R, Pedreros PA, Valdivia G, Lopez VM, Nazzal C, Alcayaga-Miranda F, Cuenca J, Brobeck MJ, Patel AN, Figueroa FE, Khoury M. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). Circ Res. 2017 Oct 27;121(10):1192-1204. doi: 10.1161/CIRCRESAHA.117.310712. Epub 2017 Sep 26.
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- UANDES-C4C
- CORFO-11IEI-9766 (Anden identifikator: Government grants)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med ucMSC
-
Affiliated Hospital to Academy of Military Medical...Ivy Institute of Stem Cells Co. LtdUkendtHjertefejl | Angina | Kronisk iskæmisk hjertesygdomKina
-
Affiliated Hospital to Academy of Military Medical...Ivy Institute of Stem Cells Co. LtdUkendtAcute respiratory distress syndrom | Akut lungeskadeKina
-
The Second Affiliated Hospital of Fujian Medical...Shanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaUkendt
-
Affiliated Hospital to Academy of Military Medical...Ivy Institute of Stem Cells Co. LtdUkendt
-
Affiliated Hospital to Academy of Military Medical...Ivy Institute of Stem Cells Co. LtdUkendtLungeskade | ParaquatforgiftningKina
-
Wuhan Union Hospital, ChinaIkke rekrutterer endnuInfektioner | Akut myeloid leukæmi | Anæmi | Blødende | Trombocytopeni | Neutropeni
-
Instituto de Medicina RegenerativaAktiv, ikke rekrutterendeCovid-19 | ARDS, menneskeMexico
-
Fuzhou General HospitalAktiv, ikke rekrutterendePrimær skleroserende kolangitis
-
Marie Hudson, MDAssistance Publique - Hôpitaux de Paris; Medical University of South Carolina og andre samarbejdspartnereRekrutteringMesenkymale stamceller | Sclerose, systemiskCanada
-
South China Research Center for Stem Cell and Regenerative...UkendtBruskskade | Degenerativ slidgigt